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Background: Dual antiplatelet therapy (DAPT) cessation increases the risk for adverse events after percutaneous coronary intervention (PCI). 
Whether this risk is uniform after stopping aspirin (ASA) or thienopyrdine alone or both agents together is unknown.
methods: The PARIS Registry (N=5,033) is a multicenter, observational study of PCI patients. Ischemic and bleeding events were adjudicated by 
an independent clinical events committee. DAPT cessation was categorized as stopping ASA, thienopyrdine, or both agents and compared events at 
1-year among groups.
results: At 1 year, 1,045 (20.8%) patients stopped antiplatelet therapy overall, 198 (3.9%) stopped ASA alone, 520 (10.3%) thienopyridine alone, 
and 327 (6.5%) stopped both agents. Cessation of both agents was more common in women, patients in US, and those with unstable angina. While 
there was no difference in stent thrombosis between groups, 1-year mortality was significantly higher in those who stopped both agents compared 
to ASA or thienopyridine alone (Figure 1). Major bleeding and MI was highest in those who stopped both agents than in those who stopped aspirin 
alone, thienopyridine alone and those on-DAPT (17.7% vs 7.1% vs 3.5%, vs 0.1% P<0.001 and 7.0% vs 3.5% vs 3.5 vs 1.4% P<0.001, respectively).
conclusions: Mortality risk due to DAPT cessation in the PARIS Registry is largely attributable to stopping both ASA and thienopyridine vs either 
agent alone, which may reflect the higher
bleeding and MI rates seen in patients who stopped both agents.
 
